- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06007781
Safety and Immunogenicity of HIL-214 in Healthy Japanese Infants
A Phase 1, Randomized, Double-blind, Multi-center, Placebo-controlled Trial to Evaluate the Safety and Immunogenicity of the Intramuscular Norovirus GI.1/GII.4 Bivalent VLP Vaccine in Healthy Japanese Infants 5 Months of Age at First Trial Vaccine Administration
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The rationale for trial NOR-109 is to evaluate the safety and immunogenicity of HIL-214 in Japanese pediatric subjects and establish whether the data obtained is consistent with that previously obtained for non-Japanese pediatric subjects.
The clinical trials for HIL-214 have so far been performed in Europe, the United States and several countries in Latin America [26]. The incidence rate of norovirus-attributable disease in Japan is at least as high as in other developed countries with the highest rates occurring in children below the age of 5 years and hospitalization most common in very young and very old populations. The inclusion of infants (5 months [±14 days] of age at the time of first trial vaccine administration) serves to compare the data obtained for infants of non-Japanese descent with Japanese infants, in alignment with the global clinical program, and to support the inclusion of Japanese infants into phase 3. Enrollment and vaccination of the infants will be performed either before or after the required routine childhood vaccines per the national immunization schedule.
This phase 1 trial in Japan aims to assess the safety and immunogenicity of two doses of HIL-214 administered 4 to 8 weeks apart, in 21 healthy infants aged 5 months at the time of the first trial vaccine dose administration. A placebo arm is included to allow an unbiased assessment of safety and immunogenicity.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Clinical Lead
- Phone Number: 6172037722
- Email: clinical.trials@hillevax.com
Study Locations
-
-
-
Fukui-Shi, Japan, 910-0833
- Fukui Aiiku Hospital
-
Iizuka-Shi, Japan, 820-0040
- Iizuka Children's Clinic
-
Kofu-Shi, Japan, 400-0853
- Childrens clinic of Kose
-
Sapporo-Shi, Japan, 062-0907
- Ohigesenseino Kodomo Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria
- Male or female subject aged 5 months [-14/+14 days].
- Infants who are in good health at the time of entry into the trial as determined by medical history, physical examination (including vital signs) and clinical judgment of the investigator.
- The subject's legally acceptable representative (LAR) signs and dates a written, informed consent form (ICF) and any required privacy authorization prior to the initiation of any trial procedures, after the nature of the trial has been explained according to local regulatory requirements.
- The subject's LAR is willing and able to comply with trial procedures and is available for the duration of follow-up.
Exclusion Criteria
- Clinically significant abnormality in growth by length/height, weight, or head circumference (according to national guidelines).
- Gastrointestinal abnormalities or any chronic gastrointestinal disease, including any uncorrected congenital malformation of the gastrointestinal tract according to medical history and/or physical examination.
- Chronic use of oral corticosteroids (equivalent to 20 mg/day prednisolone for ≥12 weeks / ≥2 mg/kg body weight /day for ≥2 weeks) within 60 days prior to Visit 1 (use of inhaled, intranasal, or topical corticosteroids are allowed).
- Use of parenteral corticosteroids (equivalent to 20 mg/day prednisolone for ≥12 weeks / ≥2 mg/kg body weight /day for ≥2 weeks. Use of inhaled, intranasal, or topical corticosteroid is allowed) within 60 days prior to Visit 1.
- Receipt of immunostimulants within 60 days prior to Visit 1.
- Receipt of parenteral, epidural, or intra-articular immunoglobulin (Ig) preparations, blood products, and/or plasma derivatives within 90 days prior to Visit 1 or planned during the full duration of the trial.
- Receipt of immunosuppressive therapy prior to Visit 1.
- Known hypersensitivity or allergy to any of the trial vaccine components (including excipients).
- Any clinically significant active infection (as assessed by the investigator) or temperature ≥38.0°C (>100.4°F), regardless of method used, within 3 days prior to intended trial vaccine administration.
- Gastroenteritis within 7 days before planned dosing (can warrant delay of trial vaccine administration).
- History of, e.g., convulsions/febrile convulsions, or any illness, that, in the opinion of the investigator, might interfere with the results of the trial or pose additional risk to the subjects due to participation the trial.
- Abnormalities of splenic or thymic function.
- Known or suspected impairment/alteration of immune function.
- Known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time.
- Receipt or scheduled receipt of any other approved or authorized vaccines within 14 days (for all non-live vaccines or oral live vaccines) or 28 days (for parenteral live vaccines) before or after trial vaccine administration.
- Participation in any clinical trial with another investigational product 30 days prior to first trial visit or intention to participate in another clinical trial at any time during the conduct of this trial.
- Seropositive for, or in evaluation for, possible human immunodeficiency virus infection.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
One dose of placebo on Day 1 and one dose of placebo between Day 29 and Day 57
|
2 injections - given on Day 1 and the second given between Day 29 - Day 57
|
Experimental: Experimental
One dose of HIL-214 on Day 1 and one dose of HIL-214 between Day 29 and Day 57
|
2 injections - given on Day 1 and the second given between Day 29 - Day 57
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary Objective
Time Frame: 3 months
|
All of the subjects in this trial will be assessed for safety of HIL-214 by comparing the occurrence and intensity of solicited and unsolicited local and systemic reactions to the study vaccine compared with placebo vaccination and including AEs leading to withdrawal of trial vaccine.
|
3 months
|
Number of subjects with solicited local AEs
Time Frame: up to 7 days post-dose 1 and dose 2.
|
Subjects that present with solicited systemic AEs.
|
up to 7 days post-dose 1 and dose 2.
|
Number of subjects with solicited Systemic AEs
Time Frame: up to 7 days post-dose 1 and dose 2.
|
Subjects that present with solicited systemic AEs.
|
up to 7 days post-dose 1 and dose 2.
|
Number of subjects with unsolicited symptomatic AEs
Time Frame: up to 28 days post-dose 1 and dose 2.
|
Subjects that present with unsolicited symptoms (AEs)
|
up to 28 days post-dose 1 and dose 2.
|
Number of subjects with AEs leading to withdrawal
Time Frame: Up to 56 days post-dose 1
|
The number of AEs that lead to vaccine dose withdrawal.
|
Up to 56 days post-dose 1
|
Number of subjects with Adverse Events and Serious Adverse Events
Time Frame: Through study completion, an average of 1 year.
|
The number of AEs and SAEs that lead to the subject's withdrawal from the trial
|
Through study completion, an average of 1 year.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NOR-109
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastroenteritis
-
GlaxoSmithKlineCompletedRotavirus Gastroenteritis | Nosocomial Rotavirus Gastroenteritis
-
National Institute of Allergy and Infectious Diseases...Completed
-
Merck Sharp & Dohme LLCCompletedRotavirus Gastroenteritis
-
VaxartCompletedNorovirus GastroenteritisUnited States
-
VaxartCompletedNorovirus GastroenteritisUnited States
-
National Institute of Allergy and Infectious Diseases...WithdrawnGastroenteritis NorovirusUnited States
-
Merck Sharp & Dohme LLCCompletedRotavirus Gastroenteritis
-
Christian Medical College, Vellore, IndiaKarolinska InstitutetCompletedRotavirus GastroenteritisIndia
-
GlaxoSmithKlineCompletedRotavirus GastroenteritisBrazil
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States